H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines (RVMD) to $73 from $72 and keeps a Buy rating on the shares following the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs
- Revolution Medicines Reports 2024 Financial Results and Progress
- Revolution Medicines reports Q4 EPS ($1.12), consensus (96c)
- Revolution Medicines sees FY25 GAAP net loss $840M-$900M
- RVMD Upcoming Earnings Report: What to Expect?